Association between nonalcoholic fatty liver disease and cardiovascular disease revealed after comprehensive control of metabolic risk factors: a nationwide population-based study in Korea

Supplemental Digital Content is available in the text. Objectives Previous epidemiological studies have limitations in revealing whether cardiovascular disease (CVD) incidence is mediated by interim occurrence of other metabolic diseases in otherwise healthy nonalcoholic fatty liver disease (NAFLD) patients. Methods The study population consisted of 334 280 healthy subjects who had had the National Health check-ups in South Korea from 2009 to 2014. The fatty liver index (FLI) was used to identify subjects with NAFLD. CVD was defined as occurrence of a composite of cardiovascular death, myocardial infarction, ischemic stroke, or coronary revascularization. The association between FLI and CVD incidence was analyzed using time-dependent Cox regression analyses. Results The study population was categorized into quartile groups according to FLI (range: Q1, 0–4.9; Q2, 5.0–12.5; Q3, 12.6–31.0; Q4, >31.0). The median follow-up duration was 5.4 years, during which subjects with higher FLIs experienced CVD more frequently than did those with lower FLIs [Q1, 215 (0.3%); Q2, 498 (0.6%); Q3, 753 (0.9%); Q4, 981 (1.2%); P < 0.001]. Adjustment of baseline characteristics revealed that a higher FLI was independently associated with an increased risk for CVD [hazard ratio between Q4 and Q1, 1.86; 95% confidence interval (CI), 1.59–2.17; P < 0.001]. The association between them remained statistically significant (hazard ratio between Q4 and Q1, 1.92; 95% CI, 1.63–2.25; P < 0.001) after further adjustment for the interim events (diabetes, hypertension, heart failure, and atrial fibrillation). Conclusions Otherwise healthy NAFLD patients progressed to develop CVD independently of the interim occurrence of other metabolic diseases, which emphasizes the importance of NAFLD as a potential therapeutic target for prevention of CVD.

[1]  Seil Oh,et al.  Validation of diagnostic codes of major clinical outcomes in a National Health Insurance database , 2019, International Journal of Arrhythmia.

[2]  K. Cusi,et al.  Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. , 2019, The lancet. Diabetes & endocrinology.

[3]  B. Nordestgaard,et al.  Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals , 2018, European heart journal.

[4]  G. Shulman,et al.  Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. , 2018, Cell metabolism.

[5]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[6]  Z. Goodman,et al.  Epidemiology and natural history of non-alcoholic fatty liver disease. , 2016, Metabolism: clinical and experimental.

[7]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[8]  J. S. Lee,et al.  Cohort Profile Cohort Profile : The National Health Insurance Service – National Sample Cohort ( NHIS-NSC ) , South Korea , 2017 .

[9]  G. Marchesini,et al.  Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. , 2015, Journal of hepatology.

[10]  Hwai I. Yang,et al.  External Validation of Fatty Liver Index for Identifying Ultrasonographic Fatty Liver in a Large-Scale Cross-Sectional Study in Taiwan , 2015, PloS one.

[11]  Giulio Marchesini,et al.  Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[12]  H. Yki-Järvinen Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[13]  R. Bloigu,et al.  Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study , 2014, BMJ Open.

[14]  N. Stefan,et al.  The role of hepatokines in metabolism , 2013, Nature Reviews Endocrinology.

[15]  Anna Castiglione,et al.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.

[16]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[17]  C. Nishida,et al.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.

[18]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.